Core Insights - Quantum BioPharma Ltd. is involved in a significant legal battle against CIBC and RBC, alleging stock market manipulation through "stock spoofing," which has led to a USD $700 million lawsuit [2][4]. - The investigative series aired by CTV News highlights the impact of stock spoofing on retail investors and the broader implications for market integrity [2][4]. Company Overview - Quantum BioPharma is a biopharmaceutical company focused on developing innovative treatments for neurodegenerative and metabolic disorders, with its lead compound, Lucid-MS, showing promise in reversing nerve cell degradation associated with multiple sclerosis [5]. - The company retains a 19.86% ownership stake in Unbuzzd Wellness Inc., which is involved in the development of a product called unbuzzd™, and has a royalty agreement that could yield up to $250 million [5]. Legal Context - The lawsuit against CIBC and RBC is based on allegations that these banks facilitated stock spoofing, with claims that over 16 million illegal orders were placed through their trading platforms [4]. - The company aims to use the exposure from the lawsuit to protect other firms and investors from similar experiences of market manipulation [4].
REPEAT: Award-winning Investigative News Program W5 Airs Part 2 of 3-part Television Series on Alleged Stock Market Manipulation of Quantum Biopharma Involving Two of Canada’s Largest Banks, CIBC and RBC